Isotretinoin (Accutane) is NOT recommended for hidradenitis suppurativa and may worsen the condition in many patients.
Isotretinoin should be avoided in treating hidradenitis suppurativa, particularly in patients with the "conglobata phenotype" of HS, as it can paradoxically aggravate the disease rather than improve it. The evidence-based guidelines for HS management do not include isotretinoin in the treatment algorithm 1, 2.
Why Isotretinoin Fails in HS
The pathophysiology of HS differs fundamentally from acne vulgaris. While isotretinoin effectively reduces sebum production and treats acne by targeting sebaceous glands, HS is primarily a follicular occlusion disorder with inflammatory components that do not respond to the same mechanisms 1. The drug's mechanism of action simply does not address the underlying pathology of HS.
Evidence Against Using Isotretinoin
Recent research demonstrates that isotretinoin can actually worsen HS in specific patient populations:
- In a 2023 study of 82 HS patients with severe acne, 12.2% reported their condition worsened on isotretinoin 3
- 90% of those who worsened were male, and 80% had the HS "conglobata phenotype" 3
- The HS "conglobata phenotype" was the strongest predictor of poor response on multivariate analysis 3
- Only 23.1% of patients who received isotretinoin after HS onset reported any effectiveness on their HS lesions 3
Limited Efficacy Data
When isotretinoin does show benefit, the response is modest and unpredictable:
- A UCLA retrospective study found only 35.9% of HS patients reported beneficial response to isotretinoin, while 64.1% had no response 4
- Another study showed 32% no response, 32% partial response, and only 36% complete response 5
- Complete response was seen ONLY in Hurley stage I and II patients; Hurley stage III patients comprised 50% of non-responders 5
Who Might Respond (If You Must Try It)
If considering isotretinoin despite the lack of guideline support, the limited evidence suggests potential responders are:
- Hurley stage I or II disease only (never stage III) 5
- Female patients 5
- Younger age 5
- Lower body weight (BMI <25 kg/m²) 3, 5
- History of pilonidal cyst 4
- HS "regular phenotype" (NOT conglobata phenotype) 3
Evidence-Based Treatment Algorithm for HS
Instead of isotretinoin, follow this guideline-based approach 1, 2:
Mild Disease (Hurley I):
- Topical Clindamycin 1% gel/solution twice daily for 12 weeks (LOE IIb, SOR B)
- OR Tetracycline 500 mg PO twice daily for 4 months (LOE IIb, SOR B)
Moderate-to-Severe Disease (Failed first-line or PGA moderate-severe):
- Clindamycin 300 mg PO twice daily + Rifampicin 600 mg PO once daily for 10 weeks (LOE III, SOR C)
If No Improvement:
- Adalimumab: 160 mg at week 0,80 mg at week 2, then 40 mg subcutaneously weekly (LOE Ib, SOR A) 1, 2
- This is the only FDA-approved biologic for HS with Level Ib evidence
Critical Safety Concerns
Beyond inefficacy, isotretinoin carries specific risks in HS patients:
- Can induce or worsen sacroiliitis and inflammatory back pain in HS patients 6
- Psychiatric side effects including severe nightmares requiring discontinuation 7
- May paradoxically worsen existing HS lesions 3, 6
Common Pitfall to Avoid
Do not assume that because a patient has both acne and HS, isotretinoin will treat both conditions. The presence of concomitant acne does NOT enhance HS treatment response to isotretinoin 4. These are distinct disease processes requiring separate treatment strategies. If the patient has true acne vulgaris requiring isotretinoin, treat it separately, but do not expect HS improvement and monitor closely for HS worsening, especially in males with conglobata phenotype.
The 2019 North American guidelines explicitly state that retinoids have limited evidence and are not part of the standard treatment algorithm for HS 2. The 2025 special populations guidelines make no mention of isotretinoin as a viable option 8.